<DOC>
	<DOCNO>NCT01203111</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy intensive insulin regimen insulin glargine insulin glulisine term change Hemoglobin A1c ( HbA1c ) level week 12 ( visit 7 ) week 24 ( visit 10 ) . Secondary Objectives : 1 . Percentage patient HbA1c &lt; 7 % week 24 . 2 . Percentage patient HbA1c &lt; 7 % symptomatic nocturnal hypoglycemia event week 24 . 3 . Fasting Plasma Glucose ( FPG ) 7-point Self Monitoring Blood Glucose ( SMBG ) week 0 , week 12 week 24 . 4 . Doses insulin glargine insulin glulisine : daily dose ( U ) daily dose / kg ( U/kg ) calculate week 24 . 5 . Systolic diastolic blood pressure , heart rate , weight change measure week 0 , week 12 week 24 . 6 . Number patient suffer hypoglycemia ( asymptomatic , symptomatic , nocturnal symptomatic , severe nocturnal severe ) evaluate treatment period . 7-Adverse event .</brief_summary>
	<brief_title>Intensive Insulin Glulisine Therapy Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin Oral Glucose-lowering Drugs</brief_title>
	<detailed_description>The study divide 3 period : 1. 2-week run-in period , 2. 12-week treatment period 1 3. 12-week treatment period 2 study treatment duration per patient : 24 week study duration per patient : 26 week</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : runin period : 1 . Uncontrolled Type 2 diabetes mellitus define HbA1c level 7,5 % 10 % assess past 6 month 2 . Male female patient 1875 year old inclusive 3 . Body Mass Index ( BMI ) 25 40 kg/m2 4 . Currently treat basal insulin ( NPH , insulin zinc insulin detemir ) , plus least 1g metformin daily , Oral Glucose Lowering Drug ( OGLD ) least 3 month 5 . Signed Informed consent obtain prior study procedure treatment period : 1 . HbA1c level 7,5 % 10 % assess week 2 week 0 2 . Serum creatinine &lt; = 135 µmol/L men &lt; = 110 µmol/L woman 3 . Alanine aminotransferase ( ALT ) and/or Aspartate aminotransferase ( AST ) &lt; = 3 time upper limit normal 4 . Negative pregnancy test woman childbearing potential Exclusion criterion : 1 . Type 1 diabetes mellitus 2 . Active proliferative diabetic retinopathy , define application photocoagulation surgery perform within 6 month study entry unstable ( rapidly progress ) retinopathy may require photocoagulation surgery study ( confirm optic fundus perform past 2 year ) 3 . Clinically relevant cardiovascular , hepatic , neurological , endocrine , major disease make implementation protocol interpretation study result difficult 4 . History impaired hepatic function define Alanine aminotransferase ( ALT ) and/or Aspartate aminotransferase ( AST ) great three time upper limit normal 5 . History impaired renal function define serum creatinine &gt; 135 µmol/l men &gt; 110 µmol/l woman 6 . History drug alcohol abuse 7 . Type 2 Diabetes Mellitus ( T2DM ) patient treat exclusively OGLDs 8 . T2DM patient treated insulin basal insulin ( Premix , rapid insulin , fastacting insulin analogue ) 9 . Previous treatment insulin glulisine 10 . Concomitant treatment thiazolidinediones , exenatide pramlintide 11 . Treatment systemic corticosteroid within 3 month prior study entry 12 . Treatment investigational product within 2 month prior study entry 13 . History hypersensitivity study drug drug similar chemical structure 14 . Presence mental condition , opinion investigator , indicate participation study best interest patient 15 . Presence geographic social condition would restrict limit patient participation duration study 16 . Pregnant breast feed woman 17 . Women childbearing potential protected effective contraceptive method birth control The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>